Formulations
Premium, sterile compounded peptides. All formulations are prepared in our 503A pharmacy using exclusively US-sourced, FDA-approved APIs.
A GLP-1 receptor agonist used in compounded form for weight management and metabolic support.
A dual GIP/GLP-1 receptor agonist for advanced metabolic and weight management protocols.
Body Protective Compound — a regenerative peptide supporting gut healing, tissue repair, and injury recovery.
Thymosin Beta-4 — promotes healing, reduces inflammation, and supports tissue regeneration.
A selective growth hormone secretagogue with minimal side effects for GH pulse optimization.
A GHRH analog that stimulates natural growth hormone production for anti-aging and recovery.
A tetrapeptide with telomere-lengthening properties studied for longevity and anti-aging applications.
A naturally occurring tripeptide-copper complex known for skin regeneration and wound healing.
Nicotinamide Adenine Dinucleotide — supports cellular energy, DNA repair, and metabolic function.
Delta Sleeping-Inducing Peptide — studied for opioid withdrawal support, chronic insomnia, and narcolepsy.
USA Current Approved Peptides & Pending Category 1 Review
Regulatory status overview for compounded peptides in the United States as of mid-2026.
Growth Hormone & Muscle
Approved Category 1 Peptides
These fully approved synthetic peptides are widely prescribed by physicians for specific indications and some off-label uses.
Semaglutide
Approved for type 2 diabetes and weight management.
Tirzepatide
Approved for type 2 diabetes and chronic weight management.
Sermorelin
Approved for growth hormone diagnostic testing.
Tesamorelin
Approved for HIV-associated lipodystrophy.
Bremelanotide (PT-141)
Approved for female sexual interest/arousal disorder.
Liraglutide
Approved for type 2 diabetes and weight management.
Interim Policy & Reclassified Peptides
Peptides Evaluated in July 2026
The FDA is splitting the review of these 12 peptides across two public meetings scheduled for July 23 and 24, 2026.
July 23, 2026 Review
BPC-157
Studied for tissue repair and gut health
KPV
Studied for inflammation and immune modulation
TB-500 (Thymosin Beta-4 fragment)
Studied for soft tissue healing
MOTs-C
Studied for metabolism and mitochondrial function
July 24, 2026 Review
Emideltide (DSIP)
Studied for sleep and stress regulation
Semax (heptapeptide)
Studied for cognitive function and neuroprotection
Epitalon
Studied for longevity and anti-aging
Extended Timeline
Remaining Peptides Under Review
While the previous seven are on the July docket, the following five peptides were also part of the initial Category 2 reclassification list and are slated for further review.
Cathelicidin LL-37
DiHexa
GHK-Cu (Injectable form)
Melanotan II
PEG-MGF (Mechano Growth Factor)
Source: FDA Category 2 reclassification review schedule. Timeline subject to change.
Are you a healthcare provider?
Sign up through VistaScripts to prescribe C3 Compounding formulations to your patients.